RNAi News and Research

RSS

Silence receives U.S. patent entitled, 'Use of Protein Kinase N beta'

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office.

16 Sep 2011

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Silence Therapeutics plc, a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA-based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer.

12 Sep 2011

New treatment strategy for dominant forms of muscular dystrophy

Investigators at The Research Institute at Nationwide Children's Hospital are studying a potential new treatment strategy for dominant forms of muscular dystrophy, thanks to preliminary funding from The Ohio State University Center for Clinical and Translational Science.

12 Sep 2011

Thermo Fisher Scientific offers siRNA libraries in Labcyte Echo qualified source plates

Labcyte Inc., a leader in miniaturization technologies for liquid handling, announced today that Thermo Fisher Scientific, the world leader in serving science, is offering the option for customers to receive siRNA (small-interfering RNA) reagent libraries in Labcyte Echo qualified source plates.

From Thermo Fisher Scientific Inc. 7 Sep 2011

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

25 Aug 2011

La Jolla Institute's new RNAi Center to focus on genetics behind myriad diseases

A major Center that will propel scientific efforts to pinpoint the specific genes involved in causing immune diseases, cancer and other diseases will be opened today at the La Jolla Institute for Allergy & Immunology.

12 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

World RNA Interference market will be worth $4 billion by 2017: New report

By 2017, the world RNA Interference market will be worth $4 billion, according to a new report available from companiesandmarkets.com.

5 Aug 2011

RNAi screen identifies Brd4 as a therapeutic target for acute myeloid leukemia

Scientists at Cold Spring Harbor Laboratory (CSHL) and five other institutions have used an unconventional approach to cancer drug discovery to identify a new potential treatment for acute myeloid leukemia.

4 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

1 Aug 2011

Myb protein suppression can help eliminate acute myelogenous leukemia

A team of scientists at Cold Spring Harbor Laboratory (CSHL) has laid bare the mechanism behind a phenomenon called oncogene addiction in mice suffering from a form of leukemia that mimics acute myelogenous leukemia (AML) in humans.

1 Aug 2011

Human kinome RNAi screening performed using Roche’s xCELLigence MP Instrument

RNA interference studies are a powerful technology for high-throughput screening. However, endpoint analyses only provide a snapshot of the analyzed cellular phenotype, as it is not possible to measure developmental changes over time.

29 Jul 2011

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.

26 Jul 2011

New transgenic mouse could predict toxicity of targeted cancer drugs

Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug.

20 Jul 2011

Researchers identify potential therapeutic target for ER-negative breast cancer

Using a new in vivo screening system, Whitehead Institute researchers have identified a protein in the serine biosynthesis pathway that is essential in estrogen receptor (ER)-negative breast cancer—a notoriously difficult disease to treat associated with low five-year survival rates.

19 Jul 2011

Disrupting protein components kills mosquitoes

Mosquitoes die soon after a blood meal if certain protein components are experimentally disrupted, a team of biochemists at the University of Arizona has discovered.

18 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

Benitec’s pain program validated by independent study

Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, announced that China-based researchers have proved the concept behind Benitec's in house neuropathic pain program.

20 Jun 2011

Scientists discover linchpin protein that drives mitochondria's calcium machinery

Mitochondria, those battery-pack organelles that fuel the energy of almost every living cell, have an insatiable appetite for calcium. Whether in a dish or a living organism, the mitochondria of most organisms eagerly absorb this chemical compound.

20 Jun 2011